fresh setback indias pharmaceutical export industry series incidents involving us washingtons food drug administration fda slapped import ban sun pharmaceutical industries plant karkhadi gujarat move sent mumbaibased drug makers shares 5 rs 574 bse thursday
ranbaxy laboratories claris wockhardt sun pharma become fourth indian pharma company face import ban us regulator last decade backdrop intellectual property row two nations use patents cheap drugs
ranbaxy controlled japans daiichi sankyo indias largest drug maker sales sun pharma leader terms market capitalization
wednesday sun pharma facility put fdas red list meaning products detained us without physical examination usually reason cited detention failure adhere good manufacturing practices fda website notification announced import crackdown give reasons ban
import alert issued usfda followup last inspection facility noncompliance current good manufacturing practice regulations identified sun pharma said
company said taken corrective steps address observations made regulator adding financial impact ban plant makes antibiotic cephalosporin would negligible
contribution facility suns consolidated revenues negligible said plant accounts less 1 consolidated revenues
company well diversified manufacturing infrastructure cater us markets contribute 54 sales financial year 2013 said said pharma analyst angel broking
